AbCellera (
ABCL$) is a unique infrastructure play in the AI-biotech space. Unlike typical biotech firms, ABCL operates as a partner to Big Pharma, using AI to decode the immune system and find rare antibodies for the world's most challenging diseases. Fundamentally, it hits the sweet spot for risk-averse growth investors: it boasts a 80% Gross Margin and maintains a Zero-Debt balance sheet with over $740M in cash. While ROE is currently negative as they build out their manufacturing capabilities, the 31% expected revenue growth and an Altman Z-Score of 14.2 make it one of the safest bets in a high-risk sector. At a 70% discount to its DCF fair value, ABCL isn't just a stock—it's an undervalued ticket to the next decade of medical breakthroughs. Watch for the accumulation phase to end as new partnership milestones are announced.
ABCL$) is a unique infrastructure play in the AI-biotech space. Unlike typical biotech firms, ABCL operates as a partner to Big Pharma, using AI to decode the immune system and find rare antibodies for the world's most challenging diseases. Fundamentally, it hits the sweet spot for risk-averse growth investors: it boasts a 80% Gross Margin and maintains a Zero-Debt balance sheet with over $740M in cash. While ROE is currently negative as they build out their manufacturing capabilities, the 31% expected revenue growth and an Altman Z-Score of 14.2 make it one of the safest bets in a high-risk sector. At a 70% discount to its DCF fair value, ABCL isn't just a stock—it's an undervalued ticket to the next decade of medical breakthroughs. Watch for the accumulation phase to end as new partnership milestones are announced.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.